(Alliance News) - Incanthera PLC said on Wednesday that operating expenses were down as it remained focussed on developing its current lead pharmaceutical product Sol towards commercialisation. Read More
(Alliance News) - Incanthera PLC on Friday reported a widened annual loss in a "very important year" for the company as it continued commercial discussion for its skin cancer asset, Sol. Read More
